Pharmafile Logo
Pharmafocus logo
Advanced Search

MabThera

Showing 11 posts of 26 posts found.

Roche's MabThera’s (rituximab)

NICE U-turn on Roche’s MabThera

May 25, 2011
Sales and Marketing MabThera, NICE, Roche

NICE has provisionally recommended Roche’s MabThera as a maintenance therapy for blood cancer patients. The new draft guidance backs MabThera’s …

News

Roche’s MabThera successor shows phase II promise

December 6, 2010
Research and Development, Sales and Marketing GA101, Genentech, GlycArt, MabThera, Roche, blood cancer, chronic lymphocytic leukaemia

The cancer drug Roche is developing as a second-generation successor to its blockbuster MabThera has shown promising results in a …

News
Roche's MabThera

NICE recommends MabThera for non-Hodgkin’s lymphoma

December 6, 2010
Sales and Marketing MabThera, NICE, Rituxan, Roche, non-Hodgkin’s lymphoma, rituximab

NICE has given a preliminary green-light to Roche’s MabThera for use as a maintenance therapy for non-Hodgkin’s lymphoma. The Institute’s …

News

MabThera gains maintenance therapy licence

October 29, 2010
Medical Communications, Sales and Marketing MabThera, Rituxan, Roche, lymphoma

Roche’s MabThera has been approved as a maintenance therapy for follicular lymphoma, a common type of blood cancer. Maintenance treatment …

News
Iressa

NICE approves trio of cancer drugs

July 28, 2010
Sales and Marketing Iressa, MabThera, NICE, Xeloda

NICE has given its final recommendation to a trio of drugs for the treatment of various cancers, which means the …

News

NICE re-thinks arthritis guidance

June 25, 2010
Sales and Marketing Enbrel, Humira, MabThera, NICE, Orencia, Remicade, TNF, rheumatoid arthritis

NICE has approved five rheumatoid arthritis treatments in certain circumstances after treatment with a tumour necrosis factor inhibitor has failed. …

News
MabThera

Roche cancer drug gets NICE thumbs up

March 5, 2010
Sales and Marketing MabThera, Roche

NICE has recommended Roche’s MabThera to treat patients with the most common form of leukaemia, relapsed or refractory chronic lymphocytic …

News

Rituxan gains approval for most common leukaemia

February 19, 2010
Sales and Marketing FDA, MabThera, Rituxan, blood cancer

Roche’s blockbuster cancer treatment MabThera/Rituxan has been approved by the FDA for the treatment of adult leukaemia. The drug earned …

News

MabThera shows improved leukaemia survival benefits

December 14, 2009
Sales and Marketing CLL, MabThera, Roche

MabThera/Rituxan is the first treatment to show improved survival in previously untreated patients with chronic lymphocytic leukaemia (CLL), according to …

News

Roche’s MabThera expands licence in leukaemia

September 4, 2009
Research and Development, Sales and Marketing MabThera, Roche

 MabThera has been approved in Europe for use in previously treated chronic lymphocytic leukaemia, which Roche says will offer new …

News

NICE approves MabThera for leukaemia

July 22, 2009
Research and Development, Sales and Marketing MabThera, NICE

NICE has approved Roche's top-selling drug MabThera as a first-line treatment for the UK's most common type of leukaemia. The …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025